HER2 Status in Breast Cancer · Observational Study

Updates and Insights on HER2 in Breast Cancer in Sohag Governorate

ClinicalTrials.gov · August 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a planned observational study registered at ClinicalTrials.gov evaluating HER2 expression patterns in breast carcinoma and their correlation with clinicopathological prognostic parameters. No results are available in this registry record; the study has not yet begun recruitment.

What was studied

Observational. HER2 Status in Breast Cancer; Female; age from 26 Years; to 85 Years. Intervention: Breast cancer female patients. n = 100. 1 site: Egypt.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a clinical trial registry record for a planned observational study with no results yet reported; it describes intended enrollment and outcome measures only.

Study design

As stated by the source record.

MethodsCohort model. Retrospective time perspective. Primary outcome measure: HER2 status in breast cancer (assessed at 2025/2026)

DesignObservational

PopulationHER2 Status in Breast Cancer; Female; age from 26 Years; to 85 Years

Sample size100

InterventionBreast cancer female patients

Setting1 site: Egypt

Reported figures

Quoted from the source exactly as published.

Planned enrollment100

Primary outcome measureHER2 status in breast cancer

Expected completion2025/2026

Caveats

This is a registry record only; no results have been reported or analysed.
Study has not yet begun recruitment (NOT_YET_RECRUITING status).
Specific eligibility criteria, methods, blinding strategy, and statistical analysis plan are not described in this registry excerpt.
Interobserver agreement assessment noted as objective but no prior validation or target threshold reported.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Observational study; no control arm or randomization described.

Directness

moderate

Aims to evaluate HER2 expression and correlate with clinicopathological parameters in breast cancer.

Consistency

insufficient

Registry record only; no results reported for consistency assessment.

Risk of bias

insufficient

No methods, blinding, or analysis plan detailed in registry record.

Sample adequacy

limited

Planned enrollment 100 participants; adequacy depends on analysis not yet disclosed.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07758127). This is a study registration, not published results. Lead sponsor: Sohag University. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 100 participants (ESTIMATED). Conditions: HER2 Status in Breast Cancer. Primary outcome measures: HER2 status in breast cancer , 2025/2026. Brief summary: * To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors. * To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes * To access interobserval agreement in HER2 score interpretation

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

HER2 Status in Breast CancerSohag UniversityNCT07758127